Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 019770106 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
TPG GP A, LLC
13D/A
Amendment 5
|
0% |
9/30/2026
Event 9/28/2026
|
|
| TPG GP A, LLC | 0% | ||
| James G. Coulter | 0% | ||
| Jon Winkelried | 0% | ||
|
Frazier Life Sciences Public Fund, L.P.
13G/A
Amendment 1
|
5.6% |
8/14/2026
Event 6/30/2026
|
|
| Frazier Life Sciences Public Fund, L.P. | 5.6% | ||
| FHMLSP, L.P. | 5.6% | ||
| FHMLSP, L.L.C. | 5.6% | ||
| Frazier Life Sciences X, L.P. | 0.1% | ||
| FHMLS X, L.P. | 0.1% | ||
| FHMLS X, L.L.C. | 0.1% | ||
| Frazier Life Sciences XI, L.P. | 0.2% | ||
| FHMLS XI, L.P. | 0.2% | ||
| FHMLS XI, L.L.C. | 0.2% | ||
| Frazier Life Sciences XII, L.P. | 0.6% | ||
| FHMLS XII, L.P. | 0.6% | ||
| FHMLS XII, L.L.C. | 0.6% | ||
| James N. Topper | 0.1% | ||
| Patrick J. Heron | 0.1% | ||
|
Belldegrun Arie
13G/A
Amendment 11
|
3.9% |
8/7/2026
Event 6/30/2026
|
|
| Arie Belldegrun, M.D. | 3.9% | ||
| Bellco Legacy LLC | 0.2% | ||
| Bellco Legacy IV LLC | 1.3% | ||
| Vida Ventures LLC | 0.5% | ||
| Vida Ventures III, L.P. | 0.5% | ||
| Vida Ventures III-A, L.P. | 0% | ||
| State Street Corp 13G | 5.5% |
8/7/2026
Event 6/30/2026
|
|
|
Citadel Advisors LLC
13G/A
Amendment 1
|
2.8% |
5/15/2026
Event 3/31/2026
|
|
| Citadel Advisors LLC | 2.4% | ||
| Citadel Advisors Holdings LP | 2.4% | ||
| Citadel GP LLC | 2.4% | ||
| Citadel Securities LLC | 0.3% | ||
| Citadel Securities Group LP | 0.4% | ||
| Citadel Securities GP LLC | 0.4% | ||
| Kenneth Griffin | 2.8% | ||
|
Lynx1 Capital Management LP
13G/A
Amendment 1
|
0% |
5/15/2026
Event 12/31/2025
|
|
| Lynx1 Capital Management LP | 0% | ||
| Weston Nichols | 0% | ||
|
Chang David D
13G/A
Amendment 1
|
4.9% |
5/13/2026
Event 3/31/2026
|
|
| David D. Chang, M.D., Ph.D. | 4.9% | ||
| Chang 2006 Family Trust | 0.5% | ||
| JEC 2019 Trust | 0.3% | ||
| RTC 2019 Trust | 0.3% | ||
|
Belldegrun Arie
13G/A
Amendment 10
|
5.4% |
5/13/2026
Event 3/31/2026
|
|
| Arie Belldegrun, M.D. | 5.4% | ||
| Bellco Legacy LLC | 0.2% | ||
| Bellco Legacy IV LLC | 1.9% | ||
| Vida Ventures LLC | 0.7% | ||
| Vida Ventures III, L.P. | 0.7% | ||
| Vida Ventures III-A, L.P. | 0% | ||
|
Frazier Life Sciences Public Fund, L.P.
13G
|
4.7% |
4/23/2026
Event 4/16/2026
|
|
| Frazier Life Sciences Public Fund, L.P. | 4.7% | ||
| FHMLSP, L.P. | 4.7% | ||
| FHMLSP, L.L.C. | 4.7% | ||
| Frazier Life Sciences X, L.P. | 0.1% | ||
| FHMLS X, L.P. | 0.1% | ||
| FHMLS X, L.L.C. | 0.1% | ||
| Frazier Life Sciences XI, L.P. | 0.2% | ||
| FHMLS XI, L.P. | 0.2% | ||
| FHMLS XI, L.L.C. | 0.2% | ||
| Frazier Life Sciences XII, L.P. | 0.5% | ||
| FHMLS XII, L.P. | 0.5% | ||
| FHMLS XII, L.L.C. | 0.5% | ||
| James N. Topper | 0.1% | ||
| Patrick J. Heron | 0.1% | ||
|
Belldegrun Arie
13G/A
Amendment 9
|
5.8% |
2/17/2026
Event 12/31/2025
|
|
| Arie Belldegrun, M.D. | 5.8% | ||
| Bellco Legacy LLC | 0.2% | ||
| Bellco Legacy IV LLC | 2.1% | ||
| Vida Ventures LLC | 0.8% | ||
| Vida Ventures III, L.P. | 0.8% | ||
| Vida Ventures III-A, L.P. | 0% | ||
|
Chang David D
13G
|
5.2% |
2/13/2026
Event 12/31/2025
|
|
| David D. Chang, M.D., Ph.D. | 5.2% | ||
| Chang 2006 Family Trust | 0.5% | ||
| JEC 2019 Trust | 0.4% | ||
| RTC 2019 Trust | 0.4% | ||
| Pfizer Inc. 13D/A Amendment 4 | 9.0% |
2/13/2026
Event 11/6/2025
|
|
| Capital World Investors 13G/A Amendment 1 | 0% |
11/13/2025
Event 9/30/2025
|
|
|
Belldegrun Arie
13G/A
Amendment 8
|
5.6% |
11/13/2025
Event 9/30/2025
|
|
| Arie Belldegrun, M.D. | 5.6% | ||
| Bellco Legacy LLC | 0.2% | ||
| Bellco Legacy IV LLC | 2.1% | ||
| Vida Ventures LLC | 0.8% | ||
| Vida Ventures III, L.P. | 0.8% | ||
| Vida Ventures III-A, L.P. | 0% | ||
|
Chang David D
13G/A
Amendment 5
|
4.9% |
11/12/2025
Event 9/30/2025
|
|
| David D. Chang, M.D., Ph.D. | 4.9% | ||
| Chang 2006 Family Trust | 0.5% | ||
| JEC 2019 Trust | 0.4% | ||
| RTC 2019 Trust | 0.4% | ||
|
Belldegrun Arie
13G/A
Amendment 7
|
5.7% |
8/12/2025
Event 6/30/2025
|
|
| Arie Belldegrun, M.D. | 5.7% | ||
| Bellco Legacy LLC | 0.2% | ||
| Bellco Legacy IV LLC | 2.1% | ||
| Vida Ventures LLC | 0.8% | ||
| Vida Ventures III, L.P. | 0.8% | ||
| Vida Ventures III-A, L.P. | 0% | ||
|
Chang David D
13G/A
Amendment 4
|
5.0% |
8/8/2025
Event 6/30/2025
|
|
| David D. Chang, M.D., Ph.D. | 5.0% | ||
| Chang 2006 Family Trust | 0.5% | ||
| JEC 2019 Trust | 0.4% | ||
| RTC 2019 Trust | 0.4% | ||
|
Citadel Advisors LLC
13G
|
6.1% |
7/16/2025
Event 7/9/2025
|
|
| Citadel Advisors LLC | 4.7% | ||
| Citadel Advisors Holdings LP | 4.7% | ||
| Citadel GP LLC | 4.7% | ||
| Citadel Securities LLC | 1.4% | ||
| Citadel Securities Group LP | 1.4% | ||
| Citadel Securities GP LLC | 1.4% | ||
| Kenneth Griffin | 6.1% | ||
| Capital World Investors 13G | 5.6% |
5/13/2025
Event 3/31/2025
|
|
|
Chang David D
13G/A
Amendment 3
|
5.0% |
5/9/2025
Event 3/31/2025
|
|
| David D. Chang, M.D., Ph.D. | 5.0% | ||
| Chang 2006 Family Trust | 0.5% | ||
| JEC 2019 Trust | 0.4% | ||
| RTC 2019 Trust | 0.4% | ||
|
Belldegrun Arie
13G/A
Amendment 6
|
5.7% |
5/9/2025
Event 3/31/2025
|
|
| Arie Belldegrun, M.D. | 5.7% | ||
| Bellco Legacy LLC | 0.2% | ||
| Bellco Legacy IV LLC | 2.1% | ||
| Vida Ventures LLC | 0.8% | ||
| Vida Ventures III, L.P. | 0.8% | ||
| Vida Ventures III-A, L.P. | 0% | ||
| BlackRock, Inc. 13G/A Amendment 2 | 5.3% |
4/17/2025
Event 3/31/2025
|
|
|
FMR LLC
13G/A
Amendment 3
|
4.9% |
3/7/2025
Event 2/28/2025
|
|
| FMR LLC | 4.9% | ||
| Abigail P. Johnson | 4.9% | ||
|
Lynx1 Capital Management LP
13G
|
5.2% |
2/14/2025
Event 12/31/2024
|
|
| Lynx1 Capital Management LP | 5.2% | ||
| Weston Nichols | 5.2% | ||
|
Belldegrun Arie
13G/A
Amendment 5
|
5.8% |
2/13/2025
Event 12/31/2024
|
|
| Arie Belldegrun, M.D. | 5.8% | ||
| Bellco Legacy LLC | 0.3% | ||
| Bellco Legacy IV LLC | 2.2% | ||
| Vida Ventures LLC | 0.8% | ||
| Vida Ventures III, L.P. | 0.8% | ||
| Vida Ventures III-A, L.P. | 0% | ||
|
Chang David D
13G/A
Amendment 2
|
5.1% |
2/13/2025
Event 12/31/2024
|
|
| David D. Chang, M.D., Ph.D. | 5.1% | ||
| Chang 2006 Family Trust | 0.6% | ||
| JEC 2019 Trust | 0.4% | ||
| RTC 2019 Trust | 0.4% | ||
|
FMR LLC
13G/A
Amendment 2
|
11.3% |
2/12/2025
Event 12/31/2024
|
|
| FMR LLC | 11.3% | ||
| Abigail P. Johnson | 11.3% |
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 3 | 19.0 k | $30.4 k |
| 2026 Q2 | 218 | 313 M | $656 M |
| 2026 Q1 | 217 | 184 M | $445 M |
| 2025 Q4 | 182 | 163 M | $223 M |
| 2025 Q3 | 178 | 163 M | $202 M |
| 2025 Q2 | 165 | 185 M | $209 M |
| 2025 Q1 | 178 | 197 M | $302 M |
| 2024 Q4 | 180 | 189 M | $402 M |
| 2024 Q3 | 163 | 168 M | $472 M |
| 2024 Q2 | 183 | 172 M | $400 M |
| 2024 Q1 | 170 | 141 M | $629 M |
| 2023 Q4 | 177 | 134 M | $431 M |
| 2023 Q3 | 159 | 130 M | $413 M |
| 2023 Q2 | 176 | 133 M | $663 M |
| 2023 Q1 | 184 | 118 M | $582 M |
| 2022 Q4 | 178 | 121 M | $759 M |
| 2022 Q3 | 203 | 106 M | $1.15 B |
| 2022 Q2 | 166 | 101 M | $1.15 B |
| 2022 Q1 | 193 | 92.1 M | $840 M |
| 2021 Q4 | 192 | 86.2 M | $1.29 B |
| 2021 Q3 | 175 | 88.0 M | $2.26 B |
| 2021 Q2 | 196 | 86.3 M | $2.25 B |
| 2021 Q1 | 180 | 89.5 M | $3.16 B |
| 2020 Q4 | 174 | 89.7 M | $2.26 B |
| 2020 Q3 | 176 | 85.3 M | $3.21 B |
| 2020 Q2 | 191 | 88.7 M | $3.80 B |
| 2020 Q1 | 123 | 73.8 M | $1.44 B |
| 2019 Q4 | 125 | 72.3 M | $1.88 B |
| 2019 Q3 | 106 | 90.1 M | $2.46 B |
| 2019 Q2 | 108 | 69.4 M | $1.86 B |
| 2019 Q1 | 96 | 65.7 M | $1.89 B |
| 2018 Q4 | 84 | 63.0 M | $1.69 B |
| 2016 Q1 | 1 | 4.03 k | $115 k |